EP1292334A4 - BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS - Google Patents

BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS

Info

Publication number
EP1292334A4
EP1292334A4 EP01939954A EP01939954A EP1292334A4 EP 1292334 A4 EP1292334 A4 EP 1292334A4 EP 01939954 A EP01939954 A EP 01939954A EP 01939954 A EP01939954 A EP 01939954A EP 1292334 A4 EP1292334 A4 EP 1292334A4
Authority
EP
European Patent Office
Prior art keywords
fusion protein
target cells
effector cell
cell killing
bispecific fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01939954A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1292334A1 (en
Inventor
Nabil Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of EP1292334A1 publication Critical patent/EP1292334A1/en
Publication of EP1292334A4 publication Critical patent/EP1292334A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
EP01939954A 2000-06-22 2001-06-04 BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS Withdrawn EP1292334A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21325200P 2000-06-22 2000-06-22
US213252P 2000-06-22
PCT/US2001/040835 WO2001097844A1 (en) 2000-06-22 2001-06-04 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells

Publications (2)

Publication Number Publication Date
EP1292334A1 EP1292334A1 (en) 2003-03-19
EP1292334A4 true EP1292334A4 (en) 2003-11-19

Family

ID=22794334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01939954A Withdrawn EP1292334A4 (en) 2000-06-22 2001-06-04 BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS

Country Status (5)

Country Link
EP (1) EP1292334A4 (ja)
JP (1) JP2003535908A (ja)
AU (2) AU6541801A (ja)
CA (1) CA2412901A1 (ja)
WO (1) WO2001097844A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307526T3 (es) 1999-08-23 2008-12-01 Chugai Seiyaku Kabushiki Kaisha Potenciadores de la expresion del antigeno hm1.24.
US7931897B2 (en) 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
ES2550621T3 (es) * 2005-02-15 2015-11-11 Duke University Anticuerpos anti-CD19 y usos en oncología
US20070003559A1 (en) * 2005-07-01 2007-01-04 Wyeth Methods of determining pharmacokinetics of targeted therapies
JP5591701B2 (ja) * 2007-09-21 2014-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 強力なアポトーシス活性および抗腫瘍活性を示すターゲティング化インターフェロン
BRPI0911427A2 (pt) * 2008-04-10 2015-11-17 Ibc Pharmaceuticals complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.
US20130058921A1 (en) * 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CN110526971B (zh) * 2013-04-29 2023-06-30 泰华制药澳大利亚公司 抗-CD38抗体和与致弱干扰素α-2B的融合体
WO2014194100A1 (en) 2013-05-29 2014-12-04 The Regents Of The University Of California Anti-cspg4 fusions with interferon for the treatment of malignancy
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL303543A (en) 2015-02-18 2023-08-01 Enlivex Therapeutics Rdo Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
PE20181323A1 (es) 2015-06-22 2018-08-14 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA3003144A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
CA3030926A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd47 combination therapy
WO2019023156A1 (en) * 2017-07-24 2019-01-31 Rutgers, The State University Of New Jersey PHOSPHATIDYLSERIN-TARGETING FUSION MOLECULES AND METHODS OF USE
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
AU2019226387A1 (en) * 2018-03-01 2020-08-20 Glycotope Gmbh Fusion protein constructs comprising an anti-MUC1 antibody and IL-15
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (en) * 1989-05-05 1990-11-07 Research Development Foundation A novel antibody delivery system for biological response modifiers
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396387A2 (en) * 1989-05-05 1990-11-07 Research Development Foundation A novel antibody delivery system for biological response modifiers
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5843439A (en) * 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
OZZELLO L ET AL: "CONJUGATION OF INTERFERON ALPHA TO A HUMANIZED MONOCLONAL ANTIBODY (HUBRE-3VL) ENHANCES THE SELECTIVE LOCALIZATION AND ANTITUMOR EFFECTS OF INTERFERON IN BREAST CANCER XENOGRAFTS", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 48, no. 2, 1998, pages 135 - 147, XP000940608, ISSN: 0167-6806 *
OZZELLO L ET AL: "EXPERIMENTAL IMMUNOTHERAPY OF BREAST CANCER USING ALPHA INTERFERON CONJUGATED TO MONOCLONAL ANTIBODY MC5", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 353, 1994, pages 35 - 46, XP000940596, ISSN: 0065-2598 *
PALLELA V R ET AL: "INTERFERON-ALPHA-2B IMMUNOCONJUGATE FOR IMPROVING IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE. NEW YORK, US, vol. 41, no. 6, June 2000 (2000-06-01), pages 1108 - 1113, XP000940586, ISSN: 0161-5505 *
See also references of WO0197844A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106065033A (zh) * 2016-03-17 2016-11-02 中国药科大学 一种细胞因子融合抗体的制备及其应用

Also Published As

Publication number Publication date
AU2001265418B2 (en) 2006-03-30
JP2003535908A (ja) 2003-12-02
CA2412901A1 (en) 2001-12-27
WO2001097844A1 (en) 2001-12-27
EP1292334A1 (en) 2003-03-19
AU6541801A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
AU6541801A (en) Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
HK1252977A1 (zh) 收集胎盤幹細胞的方法
EP1390747A4 (en) SYSTEMS AND METHOD FOR THE AUTOMATIC ANALYSIS OF CELLS AND WOVEN FABRICS
EP1002091A4 (en) NUCLEIC ACID SEQUENCE AND METHOD FOR SELECTIVE EXPRESSION OF A PROTEIN IN A TARGET CELL OR TISSUE
IL153906A0 (en) Method for direct genetic analysis of target cells
IL207008A (en) Tissues that have undergone cellular or synthetic tissue containing human placental stem cells and methods for their preparation
AU3064799A (en) Ion mobility storage trap and method
AU2003210884A8 (en) Preparations of nucleus pulposus cells and methods for their generation, identification, and use
AU2002309865A1 (en) Methods for analyzing interactions between proteins in live and intact cells
EP1482974A4 (en) ELECTROPORATION PROCESSES FOR INTRODUCING BIOACTIVE AGENTS INTO CELLS
AU2786100A (en) Method of selecting transformed cells and tissues
AU9109001A (en) Method for use of IGF-binding protein for selective sensitization of target cells in vivo
EP1464698A4 (en) HUMAN CELL CULTURE MEDIUM AND CULTIVATION PROCESS
AU1417701A (en) Soluble t cell receptor protein and method of constructing the same
AU8848998A (en) Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
IL156672A0 (en) Amphipathic peptides and their use for transferring substances of interest into cells
AU2001289603A1 (en) Methods and means for the complementation of viral protein expression in stable cell lines
AU2001236064A1 (en) Method for analysis of substances in tissue or in cells
AU2002333706A1 (en) Method and means for modulating plant cell cycle proteins and their use in plant cell growth control
EP1563073A4 (en) PROTEIN PRODUCTION METHODS AND MODIFIED CELLS FOR USE IN SUCH METHODS
HUP0102697A3 (en) Method of making proteins in transformed yeast cells
IL165662A0 (en) GP41 peptides and methods based-thereon for inhibiting HIV fusion to target cells
AU2002213954A1 (en) Method for the selective modification of peptides and proteins
AU2001267612A1 (en) Method for conditionally immortalising cells and protein constructs therefor
AU2354501A (en) A new method for the examination of protein localization in living cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/395 B

Ipc: 7C 07K 19/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20031002

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

17Q First examination report despatched

Effective date: 20050228

17Q First examination report despatched

Effective date: 20050228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN IDEC INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090723